LU83808A1 - Preparation pharmacologique de 1,6-diphosphate de fructose exercant une action therapeutique sur des patients atteints de brulures - Google Patents
Preparation pharmacologique de 1,6-diphosphate de fructose exercant une action therapeutique sur des patients atteints de brulures Download PDFInfo
- Publication number
- LU83808A1 LU83808A1 LU83808A LU83808A LU83808A1 LU 83808 A1 LU83808 A1 LU 83808A1 LU 83808 A LU83808 A LU 83808A LU 83808 A LU83808 A LU 83808A LU 83808 A1 LU83808 A1 LU 83808A1
- Authority
- LU
- Luxembourg
- Prior art keywords
- diphosphate
- burns
- patients
- fructose
- therapeutic action
- Prior art date
Links
- RNBGYGVWRKECFJ-ZXXMMSQZSA-N alpha-D-fructofuranose 1,6-bisphosphate Chemical compound O[C@H]1[C@H](O)[C@](O)(COP(O)(O)=O)O[C@@H]1COP(O)(O)=O RNBGYGVWRKECFJ-ZXXMMSQZSA-N 0.000 title claims description 12
- 229940025237 fructose 1,6-diphosphate Drugs 0.000 title claims description 12
- 238000002360 preparation method Methods 0.000 title claims description 11
- 230000000144 pharmacologic effect Effects 0.000 title claims description 9
- 230000001225 therapeutic effect Effects 0.000 title claims description 7
- 239000001177 diphosphate Substances 0.000 claims description 18
- 239000005715 Fructose Substances 0.000 claims description 17
- 159000000000 sodium salts Chemical class 0.000 claims description 9
- 229930091371 Fructose Natural products 0.000 claims description 6
- 230000037396 body weight Effects 0.000 claims description 5
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 18
- 229960002737 fructose Drugs 0.000 description 16
- 235000011180 diphosphates Nutrition 0.000 description 15
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 208000037157 Azotemia Diseases 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 238000010606 normalization Methods 0.000 description 8
- 230000002503 metabolic effect Effects 0.000 description 7
- 230000008929 regeneration Effects 0.000 description 7
- 238000011069 regeneration method Methods 0.000 description 7
- 208000035126 Facies Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 230000002641 glycemic effect Effects 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 235000021476 total parenteral nutrition Nutrition 0.000 description 4
- 239000003792 electrolyte Substances 0.000 description 3
- 230000006680 metabolic alteration Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 206010001488 Aggression Diseases 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 230000016571 aggressive behavior Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000016236 parenteral nutrition Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 241000700198 Cavia Species 0.000 description 1
- 208000032943 Fetal Distress Diseases 0.000 description 1
- 206010016855 Foetal distress syndrome Diseases 0.000 description 1
- 206010049645 Hypercatabolism Diseases 0.000 description 1
- 206010051161 Hyperglucagonaemia Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241001275831 Tanais Species 0.000 description 1
- 206010046792 Uterine hypotonus Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000011976 chest X-ray Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000004868 gas analysis Methods 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000035880 hyperglucagonemia Effects 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 238000009519 pharmacological trial Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT47554/81A IT1170618B (it) | 1981-01-13 | 1981-01-13 | Preparato farmacologico di frutto sio-1,6-difosfato ad azione terapeutica nei pazienti ustionati |
| IT4755481 | 1981-01-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU83808A1 true LU83808A1 (fr) | 1982-05-07 |
Family
ID=11261053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU83808A LU83808A1 (fr) | 1981-01-13 | 1981-12-03 | Preparation pharmacologique de 1,6-diphosphate de fructose exercant une action therapeutique sur des patients atteints de brulures |
Country Status (9)
| Country | Link |
|---|---|
| JP (1) | JPS57139016A (it) |
| AU (1) | AU7889081A (it) |
| BE (1) | BE891316A (it) |
| DE (1) | DE3150527A1 (it) |
| FR (1) | FR2497667A1 (it) |
| GB (1) | GB2092001B (it) |
| IT (1) | IT1170618B (it) |
| LU (1) | LU83808A1 (it) |
| NL (1) | NL8105073A (it) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1156103B (it) * | 1982-07-02 | 1987-01-28 | Foscama Biomed Chim Farma | Preparato di fruttosio-1,6-difosfato ad azione antiallergica |
| IT1164363B (it) * | 1983-08-03 | 1987-04-08 | Foscama Biomed Chim Farma | Procedimento terapeutico facente uso di liposomi imcorporati fruttosio 1,6 difosfato e procedimento per la preparazione degli stessi |
| IT1204764B (it) * | 1986-01-17 | 1989-03-10 | Foscama Biomed Chim Farma | Utilizzazione terapeutica del fruttosio-1,6-difosfato per la protezione nei confronti della tossicita' indotta da somministrazione di antitumorali antraciclinici |
| US4847078A (en) * | 1987-01-14 | 1989-07-11 | Arseco, Inc. | Storage stable topical composition having moisture control agent |
| CA2016709A1 (en) * | 1989-05-15 | 1990-11-15 | University Of Cincinnati | Stable aqueous solution having high concentrations of calcium and phosphate ions and solid complex |
| GB9205800D0 (en) * | 1992-03-17 | 1992-04-29 | British Tech Group | Treatment of fibrotic disorders |
| KR100836033B1 (ko) * | 2002-05-27 | 2008-06-09 | (주)아모레퍼시픽 | 프럭토스 1,6-디포스페이트 또는 그 유도체를 함유한미백용 피부외용제 조성물 |
| ITPD20060082A1 (it) * | 2006-03-13 | 2007-09-14 | Laura Martelli | Composizione ad uso cosmetico o dermatologico |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR6065M (it) * | 1966-11-25 | 1968-05-27 | ||
| US3931402A (en) * | 1970-12-02 | 1976-01-06 | Societa Prodotti Antibiotici S.P.A. | Preparations containing hexoses |
| DE2508474A1 (de) * | 1975-02-27 | 1976-09-02 | Boehringer Mannheim Gmbh | Infusions- und spuelfluessigkeiten zur behandlung von hirnoedemen |
| IT1162443B (it) * | 1979-01-16 | 1987-04-01 | Foscama Biomed Chim Farma | Sale ferrico del fruttosio-1,6-difosfato procedimento per la sua produzione e sua utilizzazione nella preparazione dell'acido fruttosio-1,6-difosforico |
| IT1143956B (it) * | 1980-03-12 | 1986-10-29 | Foscama Biomed Chim Farma | Preparato di fruttosio-1,6-difosfato ad azione protettiva della membrana degli eritrociti in pazienti sottoposti a circolazione extracorporea |
-
1981
- 1981-01-13 IT IT47554/81A patent/IT1170618B/it active
- 1981-11-10 NL NL8105073A patent/NL8105073A/nl not_active Application Discontinuation
- 1981-12-01 BE BE0/206709A patent/BE891316A/fr not_active IP Right Cessation
- 1981-12-03 LU LU83808A patent/LU83808A1/fr unknown
- 1981-12-21 DE DE19813150527 patent/DE3150527A1/de not_active Withdrawn
- 1981-12-24 AU AU78890/81A patent/AU7889081A/en not_active Abandoned
- 1981-12-30 FR FR8124524A patent/FR2497667A1/fr active Pending
-
1982
- 1982-01-07 GB GB8200440A patent/GB2092001B/en not_active Expired
- 1982-01-12 JP JP57003986A patent/JPS57139016A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS57139016A (en) | 1982-08-27 |
| BE891316A (fr) | 1982-03-31 |
| JPH0155249B2 (it) | 1989-11-22 |
| FR2497667A1 (fr) | 1982-07-16 |
| GB2092001B (en) | 1985-01-23 |
| AU7889081A (en) | 1982-07-22 |
| GB2092001A (en) | 1982-08-11 |
| IT1170618B (it) | 1987-06-03 |
| IT8147554A0 (it) | 1981-01-13 |
| NL8105073A (nl) | 1982-08-02 |
| DE3150527A1 (de) | 1982-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tsai et al. | Neuroprotective effects of recombinant human granulocyte colony-stimulating factor (G-CSF) in neurodegeneration after optic nerve crush in rats | |
| CA1327310C (fr) | Procede pour augmenter la production laitiere chez les mammiferes et/ou accroitre le poids de leurs nouveaux-nes a la naissance et ameliorer la croissance post-natale | |
| Huang et al. | Arginase-2 protects myocardial ischemiareperfusion injury via NF-κB/TNF-α pathway. | |
| JP2008533132A (ja) | ジンセノサイドを含む糖尿病または血糖調節異常の予防または治療用薬学組成物 | |
| EP4684780A1 (en) | Use of small-molecule naphthalene-ring compound | |
| FR2497667A1 (fr) | Composition therapeutique a base de fructose-1,6-diphosphate de sodium pour le traitement des brules | |
| JP2013503821A (ja) | 血栓症に対処するための医薬組成物、ならびにその調製方法および使用 | |
| FR2551659A1 (fr) | Composition retinoprotectrice a base de chlorhydrate de 2-ethyl-6-methyl-3 hydroxypyridine | |
| CH635748A5 (fr) | Procede d'obtention de cellules placentaires de brebis. | |
| JPH10502367A (ja) | 糖尿病を予防するためのｉｇｆ−ｉ又はその類似体の使用 | |
| Nabavizadeh et al. | Direct ex vivo effects of herbal extracts on serum bilirubin in neonatal blood samples | |
| KR100542809B1 (ko) | 혈당 강하용 생약 조성물, 이의 제조방법 및 이를포함하는 약학제재 | |
| TW200938216A (en) | Use of black soybean for treating ophthalmic diseases | |
| CN115531416B (zh) | 星形胶质细胞外泌体及褪黑素预处理在视神经损伤治疗中的应用 | |
| RU2143902C1 (ru) | Способ лечения метаболического синдрома х | |
| CN116747257A (zh) | 治疗或预防心功能不全或心力衰竭的中药组合物 | |
| CN1258371C (zh) | 包括大根草有机提取物的组合物及其应用 | |
| FR2551975A1 (fr) | Medicament a action antiarythmique a base de lappaconitine | |
| WO2020029221A1 (zh) | 具有抑制脂肪形成及抗氧化活性的组合物及其用途 | |
| Valente et al. | Familial histiocytic dermatoarthritis: Histologic and ultrastructural findings in two cases | |
| FR2485373A1 (fr) | Substance antivirale et procede pour sa fabrication | |
| CN115778985B (zh) | 僵蚕提取液的制备方法及应用 | |
| CN119097637B (zh) | 核桃膳食纤维在制备治疗帕金森病药物中的应用 | |
| de Knegt et al. | Encephalopathy from acute liver failure and from acute hyperammonemia in the rabbit. A clinical and biochemical study | |
| CN100450496C (zh) | 一种治疗心脑血管疾病的三七和红花复方制剂 |